Schedule 13G ownership disclosure

Fulcrum Therapeutics Inc

Common Stock, par value $0.001 per share · CUSIP: 359616109

Event date: 2025-03-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • SUVRETTA CAPITAL MANAGEMENT, LLC

    Shares: 5,067,394.00 · Class: 9.4%

  • AVERILL MASTER FUND, LTD.

    Shares: 4,635,481.00 · Class: 8.6%

  • AARON COWEN

    Shares: 5,067,394.00 · Class: 9.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000919574-25-002740
Form type
SCHEDULE 13G/A
Filer
Fulcrum Therapeutics, Inc.
CIK
CIK 1680581
Filed
May 02, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub